Summary by Moomoo AI
Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, announced the completion of a Type A meeting with the U.S. Food and Drug Administration (FDA) on January 10, 2024. The meeting focused on the company's Investigational New Drug (IND) resubmission for CMND-100, a compound designed for the treatment of Alcohol Use Disorder (AUD) using a novel psychedelic-based therapy. The CEO of Clearmind, Dr. Adi Zuloff-Shani, expressed satisfaction with the meeting's outcome and the company's eagerness to progress with the U.S. regulatory process. CMND-100's active ingredient, MEAI, has shown potential in reducing the desire for alcohol consumption while providing a euphoric experience similar to alcohol. Clearmind aims to commercialize its psychedelic-based compounds as regulated medicines and holds fifteen patent families in its intellectual portfolio. The company's shares are traded on Nasdaq, the Canadian Securities Exchange, and the Frankfurt Stock Exchange under the symbols 'CMND' and 'CWY' respectively.